Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Claris Ventures SGR is a venture capital firm established in 2019 and headquartered in Torino, Italy. The firm focuses on early-stage investments in biopharma companies that have emerged from the Italian research and development ecosystem. Claris Ventures aims to support innovation in the pharmaceutical sector by investing in companies developing transformational drugs to address significant unmet clinical needs.
Currently, Claris Ventures manages specialized venture capital funds, including Claris Biotech I and Claris Biotech II, which emphasize seed and Series A investments. The firm has a portfolio of 11 companies and is actively involved in the clinical development of these firms. Claris Ventures has established a reputation for providing not only capital but also expertise and hands-on support to facilitate clinical development programs and value creation based on clinical evidence.
Claris Ventures specializes in equity investments in early-stage biopharma companies, particularly in therapeutic areas such as oncology, immunology, and rare diseases. The firm targets seed and Series A stages, providing capital ranging from €500,000 to €3 million per investment. Claris Ventures emphasizes investments in companies that demonstrate potential for significant clinical impact and innovation.
The firm actively seeks to partner with founders who have a strong vision and a commitment to addressing unmet clinical needs. Claris Ventures values clinical evidence and aims to support the development of transformational drugs that can significantly improve patient outcomes. Their investment strategy is designed to facilitate clinical development programs and enhance the overall value of their portfolio companies.
Claris Ventures has a diverse portfolio of 11 companies, primarily focused on biopharma innovations. Notable portfolio companies include:
This portfolio reflects Claris Ventures' commitment to supporting innovative solutions in the biopharma sector, particularly those addressing significant clinical challenges.
Pietro Puglisi: Managing Partner with extensive experience in venture capital and biopharma investments.
Ciro Spedaliere: Managing Partner with a background in healthcare investments and strategic development.
Giulia Vestri: Partner specializing in early-stage biotech investments and clinical development.
Paolo Vigo: Investment Manager with expertise in financial analysis and portfolio management.
Gianmarco Pallavicini: Senior Associate focused on sourcing and evaluating investment opportunities.
Giuditta Magnifico: Associate involved in due diligence and market research.
Raffaele Troya: Finance & Administration Manager overseeing financial operations.
Araceli Albano: Internal Accounting & Administration responsible for accounting functions.
Roberto De Ponti: Senior Advisor with a wealth of experience in the biopharma sector.
Laura Iris Ferro: Senior Advisor providing strategic insights and guidance.
Manilo Marocco: Senior Advisor with a focus on investment strategy.
Michael Hodges: Entrepreneur in Residence offering mentorship to portfolio companies.
Luca Melindo: Advisor with expertise in market access and commercialization.
Cristina Tumiatti: Independent Director with a strong background in corporate governance.
To pitch to Claris Ventures, founders should send an email to info@clarisventures.com. It is advisable to include a comprehensive deck that outlines the business model, team, product, and market opportunity. Claris Ventures typically reviews pitches within a few weeks and prefers warm introductions when possible.
In recent months, Claris Ventures has been active in funding innovative projects within the biopharma sector. Notably, Haptena Therapeutics secured €3 million in seed financing to develop treatments for KRAS-driven cancers. This investment highlights Claris Ventures' commitment to supporting emerging biopharma companies and their clinical development efforts.
Additionally, Claris Ventures continues to expand its portfolio, focusing on companies that address significant unmet clinical needs. Their ongoing investments reflect a strategic approach to fostering innovation in the pharmaceutical industry.
What are Claris Ventures' investment criteria?
Claris Ventures focuses on early-stage biopharma companies, particularly in oncology, immunology, and rare diseases. They seek companies that demonstrate potential for significant clinical impact and innovation.
How can I apply or pitch to Claris Ventures?
Founders can pitch to Claris Ventures by sending an email to info@clarisventures.com. It is recommended to include a detailed business plan and information about the team and product.
What makes Claris Ventures different from other investors?
Claris Ventures provides not only capital but also expertise and hands-on support to facilitate clinical development programs. Their focus on the Italian research and development ecosystem sets them apart.
What is the geographic scope of Claris Ventures?
The firm primarily invests in companies based in Europe, particularly those emerging from the Italian biopharma sector.
What is the typical check size for investments?
Claris Ventures typically invests between €500,000 and €3 million in early-stage companies.
What is Claris Ventures' post-investment involvement?
Claris Ventures is actively involved in the clinical development of its portfolio companies, providing guidance and support to enhance their growth and success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.